Back to top
more

Merit Medical Systems (MMSI)

(Real Time Quote from BATS)

$85.46 USD

85.46
156,089

-0.19 (-0.22%)

Updated Aug 8, 2025 01:56 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 244)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Edwards Lifesciences (EW) Gains on Innovation, Margin Growth

by Zacks Equity Research

In Edwards Lifesciences' (EW) Smart Recovery portfolio, the adoption of FloTrac and ClearSight sensors remains strong.

Zacks Equity Research

Here's Why You Should Retain Inari Medical (NARI) Stock Now

by Zacks Equity Research

Inari Medical (NARI) continues benefiting from its commitment to understand the venous system. However, dependency on the wide adoption of products is a concern.

Zacks Equity Research

Here's Why You Should Retain OPKO Health (OPK) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about OPKO Health (OPK) owing to its potential in RAYALDEE.

Zacks Equity Research

Boston Scientific (BSX) Gains From New Buyouts, Cost Woes Stay

by Zacks Equity Research

Boston Scientific's (BSX) EMEA business grows above market, supported by the company's ongoing investments in emerging markets.

Zacks Equity Research

LabCorp (LH) Surpasses Q4 Earnings Estimates

by Zacks Equity Research

LabCorp (LH) delivered earnings and revenue surprises of 1.97% and 2.05%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Here's Why You Should Add Cooper Companies (COO) Stock Now

by Zacks Equity Research

Cooper Companies (COO) continues to benefit from strength in its business segments. Its acquisitions are likely to boost the top line further.

Zacks Equity Research

Quest Diagnostics (DGX) New Pact to Boost Laboratory Services

by Zacks Equity Research

Quest Diagnostics' (DGX) recent agreement is intended to offer advanced and quality clinical laboratory services in the greater New York region and beyond.

Zacks Equity Research

Reasons Why You Should Retain ResMed (RMD) Stock For Now

by Zacks Equity Research

Investors are optimistic about ResMed (RMD) owing to the increased demand for its sleep and respiratory care devices.

Zacks Equity Research

McKesson (MCK) Announces Availability of FDA-Cleared Drug for MCL

by Zacks Equity Research

The availability of the FDA-approved drug via McKesson's (MCK) independent specialty pharmacy is expected to give patients more treatment options for MCL.

Zacks Equity Research

Thermo Fisher (TMO) Rides on Strong End Markets, New Launches

by Zacks Equity Research

Thermo Fisher's (TMO) newly-launched Gibco CTS DynaCellect Magnetic Separation System is helping customers advance their cell and gene therapy programs.

Zacks Equity Research

Charles River (CRL) Introduces Novel IgY-Based ELISA Kit

by Zacks Equity Research

Charles River's (CRL) HCP-ELISA is built on its HCP-GAPex service, enhancing the efficiency and efficacy of HCP assay development.

Zacks Equity Research

ResMed's (RMD) Mask Sales Drive Growth, Margin Issue Lingers

by Zacks Equity Research

ResMed (RMD) continues to see robust demand for its market-leading mask portfolio despite being faced with challenges related to lower new patient setups from a competitor recall.

Zacks Equity Research

Here's Why You Should Retain Walgreens Boots (WBA) For Now

by Zacks Equity Research

Investors are optimistic about Walgreens Boots (WBA) on continued partnership growth and a strong focus on strategic execution.

Zacks Equity Research

Abbott (ABT) EPD Growth Continues Amid Macroeconomic Challenges

by Zacks Equity Research

At Abbott (ABT), Medical Device sales growth is led by strong performance in Electrophysiology, Structural Heart and Diabetes Care.

Zacks Equity Research

BD's (BDX) Latest Combination Test Receives the FDA's EUA

by Zacks Equity Research

BD's (BDX) new combination test is likely to significantly aid clinicians in treating patients in the current and future respiratory virus seasons.

Zacks Equity Research

3 Reasons to Retain NextGen (NXGN) Stock in Your Portfolio

by Zacks Equity Research

NextGen's (NXGN) strong product portfolio and continued demand for its solutions raise optimism about the stock.

Zacks Equity Research

LabCorp's (LH) New Launches, Planned Spinoff to Aid Growth

by Zacks Equity Research

In terms of portfolio enhancement, LabCorp (LH) enters into a collaboration with Becton, Dickinson and Company to advance in life-changing treatments for cancer and other diseases.

Zacks Equity Research

Zacks Industry Outlook Highlights McKesson, AmerisourceBergen, LabCorp, Cardinal Health and Merit Medical

by Zacks Equity Research

McKesson, AmerisourceBergen, LabCorp, Cardinal Health and Merit Medical have been highlighted in this Industry Outlook article.

Indrajit Bandyopadhyay headshot

5 Dental Supplies Stocks to Buy Amid Recovering Prospects

by Indrajit Bandyopadhyay

Here, we discuss five stocks from the Dental Supplies industry that are likely to create wealth for investors - MCK, ABC, LH, CAH and MMSI.

Zacks Equity Research

Hologic (HOLX) Q1 Earnings Beat Estimates, 2023 View Up

by Zacks Equity Research

Lower COVID-19 assays sales and supply chain challenges related to semiconductor chips dent Hologic's (HOLX) top line in Q1.

Zacks Equity Research

Thermo Fisher (TMO) Q4 Earnings Beat Estimates, Margins Down

by Zacks Equity Research

Robust year-over-year growth in the Analytical Instruments and the Laboratory Products and Biopharma Services segments boost Thermo Fisher's (TMO) Q4 revenues.

Zacks Equity Research

Integer Holdings (ITGR) Announces Solid Preliminary Q4 Revenues

by Zacks Equity Research

Integer Holdings' (ITGR) revenue growth in the fourth quarter is likely to have been boosted by continued strong customer demand for its products.

Zacks Equity Research

Here's Why You Should Retain Nevro (NVRO) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Nevro (NVRO), owing to its R&D edge.

Zacks Equity Research

MMSI or ALGN: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

MMSI vs. ALGN: Which Stock Is the Better Value Option?

Zacks Equity Research

Here's Why You Should Retain DaVita (DVA) Stock for Now

by Zacks Equity Research

Investors remain optimistic about DaVita (DVA) due to the strength in its DaVita Kidney Care.